Maynard Um
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $300 at Oppenheimer
-
-
-
-
-
-
-
Freedom Broker Upgrades Biogen (BIIB) to Buy, raises PT to $245
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $203 at BofA Securities
-
-
-
-
-
-
-
Biogen acquires TJ Biopharma's felzartamab rights in China for $850M
-
-
-
-
-
-
-
William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform
-
-
-
-
-
-
-
Biogen will introduce 28 mg vial at same price as 12 mg vial, resulting in parity pricing for patients in the maintenance phase - Spokesperson
-
-
-
-
-
-
-
Biogen reports positive salanersen trial results in SMA patients
-
401,682 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

